Targeting of the DNA repair pathways in cancer alone is also of high interest, as cancers are characteristically genetically unstable and generally have impaired DNA repair (e.g., BRCA and ATM mutants) and thus rely more heavily on alternative repair pathways to survive during chemotherapy (7). The gene discussed is ATM; the disease is cancer.